Abstract
Much of the literature on therapeutic somatic cell nuclear transfer covers the moral arguments for and against proceeding and the policy stall occasioned by conflicts over the moral status of embryos. Yet it is also worthwhile to view policy from the standpoint of the resources available as well as of deficiencies in those resources. This article uses the idea of a policy community to examine policy making from a starting point that focuses not on what divides, but rather on the groups and individuals committed to enabling ES cell research and therapeutic SCNT. Although written with international dimensions in mind, the article focuses on the United States, where the politics are particularly volatile and the likelihood of policy leadership at the national level is remote.